For research use only. Not for therapeutic Use.
epi-Canagliflozin (CAT: C000594) is an epimeric impurity of Canagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes and obesity. Canagliflozin works by inhibiting the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and improved glycemic control. epi-Canagliflozin is a closely related compound that may result from a stereochemical alteration during the synthesis of Canagliflozin.
Catalog Number | C000594 |
CAS Number | 1589590-87-3 |
Synonyms | (1R)-1,5-Anhydro-1-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-D-glucitol; |
Molecular Formula | C₂₄H₂₅FO₅S |
Purity | ≥95% |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | White to Off-White Solid |
Storage | -20°C, Hygroscopic |
Reference | Chao, E. et al.: Drug Fut., 36, 351 (2011); Sha, S. et al.: Diab. Obes. Metab., 13, 669 (2011); Kipnes, M.S.: Clin. Invest., 1, 145 (2011); |